Antidiabetics Market Size to Worth Around USD 75 Billion by 2030
The report analyzes and forecasts the Antidiabetics Market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2022 to 2030. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Antidiabetics Market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Antidiabetics Market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Antidiabetics Market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Download Sample Report Copy From Here:https://www.acumenresearchandconsulting.com/request-sample/2408
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding. Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
Market Players as below:
Participants include major global players Novartis AG, Novo Nordisk A/S, Johnson & Johnson, AstraZeneca, Merck & Co. Inc., Pfizer. Sanofi, and Others.
The major market segments of Antidiabetics Market are as below:
Antidiabetics Market By Type
Insulin
- Long acting analog
- Rapid acting analog
- Short acting analog
- Premixed insulin
- Intermediate acting insulin
Drug class
- Alpha glucosidase inhibitors
- DPP-IV (Dipeptidyl Peptidase) inhibitors
- GLP-1 (Glucagon like peptide) agonists
- Sulphonylureas
- Biguanides
- Thiazolidinedione
- Meglitinides
- SGLT-II (Sodium Glucose Transport Proteins) inhibitors
Antidiabetics Market By Mode of Administration
Insulin syringe / Insulin pen
Insulin pump
Intravenous infusion
Oral
Others
Ask Query Here: richard@acumenresearchandconsulting.com or sales@acumenresearchandconsulting.com
Table Of Contents:
CHAPTER 1. Industry Overview of Antidiabetics
1.1. Definition and Scope
1.1.1. Definition of Antidiabetics
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Antidiabetics Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Antidiabetics Market By Type
1.2.3. Antidiabetics Market By Mode of Administration
1.2.4. Antidiabetics Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Antidiabetics Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Antidiabetics Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Antidiabetics Major Manufacturers in 2019
CHAPTER 5. Antidiabetics Market By Type
5.1. Introduction
5.2. Antidiabetics Revenue By Type
5.2.1. Antidiabetics Revenue (US$ Mn) and Forecast, By Type, 2016-2027
5.2.2. Insulin
5.2.2.1. Insulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.1. Long acting analog
5.2.2.1.1.1. Long acting analog Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.2. Rapid acting analog
5.2.2.1.2.1. Rapid acting analog Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.3. Short acting analog
5.2.2.1.3.1. Short acting analog Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.4. Premixed insulin
5.2.2.1.4.1. Premixed insulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.2.1.5. Intermediate acting insulin
5.2.2.1.5.1. Intermediate acting insulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Drug class
5.2.3.1. Drug class Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.1.1. Alpha glucosidase inhibitors
5.2.3.2. Alpha glucosidase inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.2.1. DPP-IV (Dipeptidyl Peptidase) inhibitors
5.2.3.3. DPP-IV (Dipeptidyl Peptidase) inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.3.1. GLP-1 (Glucagon like peptide) agonists
5.2.3.4. GLP-1 (Glucagon like peptide) agonists Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.4.1. Sulphonylureas
5.2.3.5. Sulphonylureas Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.5.1. Biguanides
5.2.3.6. Biguanides Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.6.1. Thiazolidinedione
5.2.3.7. Thiazolidinedione Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.7.1. Meglitinides
5.2.3.8. Meglitinides Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3.8.1. SGLT-II (Sodium Glucose Transport Proteins) inhibitors
5.2.3.9. SGLT-II (Sodium Glucose Transport Proteins) inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Antidiabetics Market Revenue By Mode of Administration
6.1. Introduction
6.2. Antidiabetics Revenue (US$ Mn) By Mode of Administration
6.2.1. Antidiabetics Revenue (US$ Mn) and Forecast By End Use, 2016 – 2027
6.2.2. Insulin syringe/ Insulin pen
6.2.2.1. Insulin syringe/ Insulin pen Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Insulin pump
6.2.3.1. Insulin pump Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Intravenous infusion
6.2.4.1. Intravenous infusion Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Oral
6.2.5.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.6. Others
6.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. North America Antidiabetics Market By Country
7.1. North America Antidiabetics Overview
7.2. U.S.
7.2.1. U.S. Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.2.2. U.S. Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
7.3. Canada
7.3.1. Canada Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
7.3.2. Canada Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
7.4. North America PEST Analysis
CHAPTER 8. Europe Antidiabetics Market By Country
8.1. Europe Antidiabetics Testing Services Market Overview
8.2. U.K.
8.2.1. U.K. Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.2. U.K. Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.3. Germany
8.3.1. Germany Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.2. Germany Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.4. France
8.4.1. France Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.4.2. France Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.5. Spain
8.5.1. Spain Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.5.2. Spain Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.6. Rest of Europe
8.6.1. Rest of Europe Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.6.2. Rest of Europe Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016-2027
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Antidiabetics Market By Country
9.1. Asia Pacific Antidiabetics Market Overview
9.2. China
9.2.1. China Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.2.2. China Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
9.3. Japan
9.3.1. Japan Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.3.2. Japan Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
9.4. India
9.4.1. India Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.4.2. India Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
9.5. Australia
9.5.1. Australia Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.5.2. Australia Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
9.6. South Korea
9.6.1. South Korea Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.6.2. South Korea Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
9.7.2. Rest of Asia-Pacific Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Antidiabetics Market By Country
10.1. Latin America Antidiabetics Market Overview
10.2. Brazil
10.2.1. Brazil Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.2.2. Brazil Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
10.3. Mexico
10.3.1. Mexico Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.3.2. Mexico Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
10.4. Rest of Latin America
10.4.1. Rest of Latin America Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
10.4.2. Rest of Latin America Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
CHAPTER 11. Middle East & Africa Antidiabetics Market By Country
11.1. Middle East & Africa Antidiabetics Market Overview
11.2. Saudi Arabia
11.2.1. Saudi Arabia Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
11.2.2. Saudi Arabia Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
11.3. UAE
11.3.1. UAE Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
11.3.2. UAE Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Antidiabetics Market Revenue (US$ Mn) and Forecast By Type, 2016 – 2027
11.4.2. Rest of Middle East & Africa Antidiabetics Market Revenue (US$ Mn) and Forecast By Mode of Administration, 2016 – 2027
CHAPTER 12. PLAYER ANALYSIS OF STROKE MANAGEMENT
12.1. Antidiabetics Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Antidiabetics Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. COMPANY PROFILE
13.1. Novartis AG
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (US$ Mn), 2019
13.1.3.2. Novartis AG 2019 Antidiabetics Business Regional Distribution
13.1.4. Product/ Service and Specification
13.1.5. Recent Developments & Business Strategy
13.1.6. Manufacturing Plant Footprint Analysis
13.2. Novo Nordisk A/S
13.3. Johnson & Johnson
13.4. AstraZeneca
13.5. Merck & Co. Inc.
13.6. Pfizer
13.7. Sanofi
13.8. Others
To Get Premium Report Full Copy in Form of Single user or Multiple user@https://www.acumenresearchandconsulting.com/buy-now/0/2408
About Us:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.
